

NGM Bio Plans to Initiate Registrational Trial in Primary Sclerosing Cholangitis & Phase 2 Trial in Hyperemesis Gravidarum in Q4 2024

Program	Mechanism	Indication	Preclinical	Phase 1	Phase 2	Status
Aldafermin	FGF19 Analog	Primary Sclerosing Cholangitis (PSC)			PHASE 2 COMPLETE. DISCUSSING REGISTRATIONAL PHASE 2/3 WITH FDA	Targeting FPI in 4Q24. Received Orphan Drug Designation
NGM120	GFRAL Antagonist Antibody	Hyperemesis Gravidarum (HG)			PHASE 2 PLANNING	Targeting FPI in 4Q24
NGM707 + pembrolizumab	ILT2/ILT4 Dual Antagonist + PD-1 Antagonist Antibody	Advanced Solid Tumors			PHASE 1/2	Additional Ph1b Data in 3Q24